BOLT [NASD]
Bolt Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own9.80% Shs Outstand37.45M Perf Week-8.84%
Market Cap52.88M Forward P/E- EPS next Y-2.04 Insider Trans0.00% Shs Float35.19M Perf Month-15.19%
Income-95.30M PEG- EPS next Q-0.60 Inst Own68.00% Short Float / Ratio4.25% / 5.22 Perf Quarter4.69%
Sales4.80M P/S11.02 EPS this Y-57.70% Inst Trans-0.16% Short Interest1.50M Perf Half Y-23.43%
Book/sh5.03 P/B0.27 EPS next Y15.00% ROA-34.80% Target Price5.00 Perf Year-54.11%
Cash/sh4.34 P/C0.31 EPS next 5Y- ROE-43.60% 52W Range1.18 - 3.14 Perf YTD3.08%
Dividend- P/FCF- EPS past 5Y- ROI-37.10% 52W High-57.32% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low13.56% ATR0.10
Employees91 Current Ratio7.20 Sales Q/Q162.50% Oper. Margin- RSI (14)41.87 Volatility6.02% 7.39%
OptionableNo Debt/Eq0.00 EPS Q/Q7.60% Profit Margin- Rel Volume0.26 Prev Close1.31
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume286.84K Price1.34
Recom2.00 SMA20-11.14% SMA50-9.65% SMA200-19.97% Volume74,037 Change2.29%
Jan-06-22Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21Initiated SVB Leerink Outperform $36
Mar-02-21Initiated Stifel Buy $40
Mar-02-21Initiated Morgan Stanley Overweight $45
Mar-02-21Initiated Guggenheim Buy $42
Mar-14-23 04:30PM
Feb-28-23 08:00AM
Feb-01-23 08:00AM
Jan-04-23 09:31AM
Dec-14-22 04:43PM
04:05PM Loading…
Nov-10-22 04:05PM
Nov-07-22 08:00AM
Nov-02-22 07:20AM
Nov-01-22 10:01AM
08:00AM
Sep-09-22 12:08PM
Aug-31-22 07:30AM
Aug-25-22 12:23PM
12:02PM
Aug-10-22 04:05PM
08:44AM Loading…
Jul-22-22 08:44AM
Jun-10-22 07:21AM
May-27-22 08:00AM
May-26-22 06:52AM
May-13-22 08:28AM
May-12-22 04:05PM
May-11-22 07:32AM
Apr-07-22 08:00AM
Mar-30-22 04:05PM
Mar-08-22 04:30PM
Feb-12-22 06:30AM
Feb-02-22 08:00AM
Jan-27-22 01:43PM
Jan-06-22 08:00AM
Dec-17-21 06:14AM
08:00AM Loading…
Dec-16-21 08:00AM
Dec-06-21 04:29PM
09:23AM
06:00AM
Dec-02-21 06:00AM
Nov-19-21 08:00AM
Nov-12-21 07:00AM
Nov-09-21 04:05AM
Nov-08-21 08:00AM
Nov-03-21 08:00AM
Oct-01-21 08:00AM
Sep-08-21 07:30AM
Sep-02-21 08:00AM
Aug-27-21 05:55AM
Aug-26-21 04:05PM
Aug-16-21 06:26AM
Aug-12-21 04:05PM
Aug-02-21 04:32PM
Jul-20-21 12:42AM
Jun-22-21 08:16PM
08:00PM
06:20PM
05:33PM
03:41PM
02:10PM
01:03PM
12:30PM
12:11PM
12:00PM
11:33AM
11:24AM
11:00AM
09:24AM
08:00AM
05:22AM
02:00AM
Jun-21-21 10:43PM
08:00PM
07:36PM
05:43PM
04:12PM
02:25PM
01:40PM
01:30PM
11:30AM
11:23AM
11:00AM
10:25AM
09:23AM
05:51AM
Jun-20-21 03:25PM
03:00PM
12:37PM
03:43AM
Jun-19-21 08:01PM
05:16PM
Jun-18-21 10:50PM
08:25PM
06:45PM
05:57PM
12:00PM
11:30AM
11:28AM
11:00AM
07:30AM
Jun-04-21 09:00AM
Jun-02-21 08:00AM
May-13-21 04:05PM
May-05-21 02:31AM
Apr-10-21 08:30AM
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerJul 13Sale2.00800,0001,600,0003,703,991Jul 15 04:16 PM